Allergan Plc (AGN)

160.22
NYSE : Health Technology
Prev Close 156.56
Day Low/High 156.32 / 160.66
52 Wk Low/High 125.84 / 197.00
Avg Volume 2.54M
Exchange NYSE
Shares Outstanding 337.29M
Market Cap 52.81B
EPS -13.20
P/E Ratio 20.23
Div & Yield 2.88 (1.88%)
Allergan To Present At Credit Suisse 27th Annual Healthcare Conference

Allergan To Present At Credit Suisse 27th Annual Healthcare Conference

DUBLIN, Nov. 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Credit Suisse 27 th Annual Health Care Conference in Scottsdale,...

Allergan Needs to Rebase on the Charts - Don't Rush It

Allergan Needs to Rebase on the Charts - Don't Rush It

Let's check the charts and technical indicators for some guidance.

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Allergan Shares Fall Despite Q3 Beat, Increased Guidance

Allergan Shares Fall Despite Q3 Beat, Increased Guidance

The Dublin firm raised its outlook amid a delay in the launch of generic competition to its dry eye medication Restasis.

US Stocks Rebound as Earnings Drive Sentiment Amid Renewed Trade War Concerns

US Stocks Rebound as Earnings Drive Sentiment Amid Renewed Trade War Concerns

Global stocks attempted yet another rebound Tuesday, with reports of direction market intervention in China supporting prices in Asia and stronger-than-expected blue chip earnings putting European bourses on solid footing following a volatile session on Wall Street that saw a 900-point swing for the Dow Jones Industrial Average and a further worrying plunge in big-name tech companies.

Staying Long Apple Into Tuesday's Product Launch: Market Recon

Staying Long Apple Into Tuesday's Product Launch: Market Recon

My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.

Allergan Reports Third Quarter 2018 Results Including GAAP Net Revenues Of $3.9 Billion

Allergan Reports Third Quarter 2018 Results Including GAAP Net Revenues Of $3.9 Billion

- Q3 2018 GAAP Loss Per Share of $0.11; Non-GAAP Performance Net Income Per Share of $4.25 -

Allergan Declares Fourth Quarter 2018 Cash Dividend Of $0.72 Per Ordinary Share

Allergan Declares Fourth Quarter 2018 Cash Dividend Of $0.72 Per Ordinary Share

- Dividend to be Paid on December 14, 2018 -

Procter & Gamble, Western Digital, Allergan: 'Mad Money' Lightning Round

Procter & Gamble, Western Digital, Allergan: 'Mad Money' Lightning Round

Jim Cramer weighs in on Procter & Gamble, Six Flags, Western Digital, Allergan, Principal Financial Group.

Risk and Uncertainty: Cramer's 'Mad Money' Recap (Monday 7/30/18)

Risk and Uncertainty: Cramer's 'Mad Money' Recap (Monday 7/30/18)

Jim Cramer says somebody panicked, and their departure left behind a mess in the tech sector. But that spells a buying opportunity.

CoolSculpting® And Kristin Davis Partner To Overcome Denim Denial Blues

CoolSculpting® And Kristin Davis Partner To Overcome Denim Denial Blues

-- Actress Named as Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --

Allergan And The Allergan Foundation Support U.S. Veterans With "Heroes MAKE America" Sponsorship

Allergan And The Allergan Foundation Support U.S. Veterans With "Heroes MAKE America" Sponsorship

- The Manufacturing Institute's Career Skills Program Connects Veterans with Potential Manufacturing Jobs -

Allergan To Showcase Continued Eye Care Innovation With New Data On Investigational Medicines At The American Academy Of Ophthalmology Annual Meeting

Allergan To Showcase Continued Eye Care Innovation With New Data On Investigational Medicines At The American Academy Of Ophthalmology Annual Meeting

- Allergan Hosting Analyst Event at the 2018 AAO Annual Meeting Including Conference Call and Webcast on Friday, October 26, at 6:30 p.m. Central Time (7:30 p.m. Eastern Time) -

Allergan Announces Completion Of Two Positive Safety Studies For Ubrogepant - An Oral CGRP Receptor Antagonist For The Acute Treatment Of Migraine

Allergan Announces Completion Of Two Positive Safety Studies For Ubrogepant - An Oral CGRP Receptor Antagonist For The Acute Treatment Of Migraine

--One-year study continues to support positive safety and tolerability profile for ubrogepant--

FDA Approves Medicines360's SNDA For LILETTA® (levonorgestrel-releasing Intrauterine System) 52 Mg To Prevent Pregnancy For Up To Five Years

FDA Approves Medicines360's SNDA For LILETTA® (levonorgestrel-releasing Intrauterine System) 52 Mg To Prevent Pregnancy For Up To Five Years

DUBLIN and SAN FRANCISCO, Oct. 16, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines,...

Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix

Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix

DUBLIN, Oct. 11, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October...

Allergan Presents New Research At The American College Of Gastroenterology Annual Scientific Meeting (ACG 2018)

Allergan Presents New Research At The American College Of Gastroenterology Annual Scientific Meeting (ACG 2018)

DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific Meeting (ACG),...

Allergan Launches Personalized Study Approach For Clinical Research Programs In Inflammatory Bowel Disease

Allergan Launches Personalized Study Approach For Clinical Research Programs In Inflammatory Bowel Disease

- New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab

Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting®

Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting®

DUBLIN, Oct. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting ® treatment received FDA clearance to treat the submandibular area.

Aegon: Transamerica Settles Universal Life Litigation

Aegon: Transamerica Settles Universal Life Litigation

Aegon's subsidiary Transamerica today announces an agreement that would resolve litigation challenging certain monthly deduction rate adjustments on universal life insurance policies in the United States.

Allergan Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generation Of Consumers

Allergan Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generation Of Consumers

Bigger, bolder JUVÉDERM® campaign seeks to make JUVÉDERM® a household name for consumers

Allergan To Report Third Quarter 2018 Earnings And Host Conference Call And Webcast

Allergan To Report Third Quarter 2018 Earnings And Host Conference Call And Webcast

DUBLIN, Oct. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018, prior to the open of U.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs

Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs

Allergan Foundation pledges $2,000,000 to support breast health research

Allergan Announces FDA Acceptance Of Supplemental New Drug Application For VRAYLAR® (cariprazine)

Allergan Announces FDA Acceptance Of Supplemental New Drug Application For VRAYLAR® (cariprazine)

- Application Seeks to Expand VRAYLAR Indication to Include the Treatment of Bipolar Depression -

Aegon's US Capital Position To Benefit Significantly From Merger Of Legal Entities

Aegon's US Capital Position To Benefit Significantly From Merger Of Legal Entities

Aegon expects a one-time benefit to capital generation of approximately USD 1 billion as a result of the merger of two legal entities.

A Bullish Options Play on Allergan

A Bullish Options Play on Allergan

Buyout rumors aside, AGN is a name I still find attractive.

Allergan Teams Up With Actor Scott Eastwood To Encourage Recognition Of World Alzheimer's Day On September 21st

Allergan Teams Up With Actor Scott Eastwood To Encourage Recognition Of World Alzheimer's Day On September 21st

The company and actor join forces to pay homage to those affected by Alzheimer's Disease

Aegon Announces Purchase Of Shares To Neutralize 2018 Interim Stock Dividend

Aegon Announces Purchase Of Shares To Neutralize 2018 Interim Stock Dividend

Aegon will repurchase 24,133,950 common shares to neutralize the dilutive effect of the 2018 interim stock dividend.

TheStreet Quant Rating: C (Hold)